

Appendix 1

Table A1: Estimated resident populations by place of birth, sex and year for NSW 1991 to 2001

Sex	Year										
	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
China											
M	26,161	28,739	29,293	30,220	31,677	35,070	39,336	43,655	46,605	49,183	51,726
F	22,216	26,178	27,762	29,264	31,202	36,544	41,483	46,063	49,893	53,507	57,081
Total	48,377	54,917	57,055	59,484	62,879	71,614	80,819	89,718	96,498	102,690	108,807
Egypt											
M	10,065	10,163	10,141	10,100	10,098	10,088	10,198	10,045	10,121	10,276	10,428
F	9,282	9,367	9,385	9,396	9,413	9,446	9,566	9,439	9,570	9,780	9,983
Total	19,347	19,530	19,526	19,496	19,511	19,534	19,764	19,484	19,691	20,056	20,411
Fiji											
M	10,023	10,413	10,570	10,849	11,250	11,747	11,723	11,209	11,118	11,175	11,226
F	10,679	11,199	11,462	11,821	12,341	12,962	13,029	12,522	12,532	12,715	12,891
Total	20,702	21,612	22,032	22,670	23,591	24,709	24,752	23,731	23,650	23,890	24,117
Germany											
M	17,478	17,373	17,257	17,232	17,215	17,290	17,409	17,689	17,368	16,897	16,461
F	18,313	18,277	18,233	18,216	18,247	18,317	18,408	18,621	18,176	17,555	16,950
Total	35,791	35,650	35,490	35,448	35,462	35,607	35,817	36,310	35,544	34,452	33,411
Greece											
M	24,557	24,292	24,028	23,804	23,605	23,463	23,493	23,266	23,410	23,667	23,912
F	23,423	23,247	23,053	22,903	22,746	22,702	22,799	22,661	22,885	23,216	23,529
Total	47,980	47,539	47,081	46,707	46,351	46,165	46,292	45,927	46,295	46,883	47,441
Hong Kong and Macau											
M	17,037	19,566	20,413	20,793	21,309	22,030	16,081	15,207	13,897	12,066	10,382
F	17,488	19,901	20,715	21,165	21,998	23,058	17,273	16,507	15,373	13,720	12,202
Total	34,525	39,467	41,128	41,958	43,307	45,088	33,354	31,714	29,270	25,786	22,584
India											
M	11,416	12,526	13,230	14,010	15,241	16,627	18,210	19,914	22,515	25,467	28,544
F	10,705	11,654	12,245	12,861	13,807	14,796	15,951	16,775	18,238	19,932	21,658
Total	22,121	24,180	25,475	26,871	29,048	31,423	34,161	36,689	40,753	45,399	50,202
Indonesia											
M	8,211	8,357	8,461	8,668	9,098	9,754	9,440	10,852	11,219	11,153	11,048
F	7,469	7,670	7,841	8,101	8,639	9,323	9,084	10,457	11,173	11,531	11,814
Total	15,680	16,027	16,302	16,769	17,737	19,077	18,524	21,309	22,392	22,684	22,862
Italy											
M	40,817	40,427	40,048	39,694	39,333	38,950	38,240	37,154	36,682	36,363	36,019
F	34,747	34,422	34,102	33,778	33,412	33,064	32,523	31,646	31,381	31,264	31,109
Total	75,564	74,849	74,150	73,472	72,745	72,014	70,763	68,800	68,063	67,627	67,128
Korea											
M	8,809	9,443	9,744	10,122	10,771	11,604	12,669	13,264	13,691	14,094	14,473
F	8,589	9,396	10,018	10,692	11,393	12,184	13,237	13,780	14,176	14,569	14,956
Total	17,398	18,839	19,762	20,814	22,164	23,788	25,906	27,044	27,867	28,663	29,429
Lebanon											
M	31,003	30,854	30,507	30,313	30,269	30,293	29,848	30,199	30,838	31,498	32,142
F	27,689	27,603	27,436	27,332	27,304	27,392	27,019	27,353	27,972	28,595	29,205
Total	58,692	58,457	57,943	57,645	57,573	57,685	56,867	57,552	58,810	60,093	61,347
Malaysia and Brunei											
M	10,890	10,808	10,607	10,678	10,746	10,909	10,914	11,153	11,349	11,495	11,613
F	11,188	11,286	11,231	11,358	11,564	11,901	12,090	12,503	12,902	13,302	13,710
Total	22,078	22,094	21,838	22,036	22,310	22,810	23,004	23,656	24,251	24,797	25,323

Table A1: Estimated resident populations by place of birth, sex and year for NSW 1991 to 2001 (continued)

Sex	Year										
	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Malta											
M	11,654	11,642	11,610	11,616	11,635	11,648	11,585	11,675	11,522	11,292	11,056
F	10,193	10,240	10,277	10,336	10,393	10,483	10,439	10,571	10,460	10,276	10,106
Total	21,847	21,882	21,887	21,952	22,028	22,131	22,024	22,246	21,982	21,568	21,162
Netherlands											
M	13,221	13,003	12,765	12,588	12,464	12,353	12,353	11,976	11,700	11,482	11,257
F	11,752	11,553	11,343	11,189	11,067	10,953	11,003	10,647	10,390	10,191	9,996
Total	24,973	24,556	24,108	23,777	23,531	23,306	23,356	22,623	22,090	21,673	21,253
New Zealand											
M	45,056	44,869	44,809	45,313	46,449	48,021	49,909	52,163	54,474	56,837	59,228
F	44,042	43,908	43,941	44,506	45,791	47,532	49,494	51,875	53,931	55,892	57,872
Total	89,098	88,777	88,750	89,819	92,240	95,553	99,403	104,038	108,405	112,729	117,100
Philippines											
M	16,030	17,268	17,892	18,811	19,839	20,681	22,661	23,832	25,604	27,636	29,683
F	24,414	26,428	27,554	28,920	30,412	31,693	33,430	34,435	35,914	37,574	39,223
Total	40,444	43,696	45,446	47,731	50,251	52,374	56,091	58,267	61,518	65,210	68,906
Poland											
M	10,676	10,638	10,469	10,348	10,253	10,136	10,077	9,879	9,599	9,286	8,950
F	9,937	10,135	10,212	10,306	10,442	10,541	10,650	10,610	10,444	10,232	9,995
Total	20,613	20,773	20,681	20,654	20,695	20,677	20,727	20,489	20,043	19,518	18,945
Portugal											
M	5,442	5,425	5,350	5,349	5,409	5,473	5,344	5,017	4,944	4,950	4,943
F	4,884	4,917	4,893	4,906	4,968	5,086	4,953	4,632	4,566	4,574	4,563
Total	10,326	10,342	10,243	10,255	10,377	10,559	10,297	9,649	9,510	9,524	9,506
South Africa											
M	10,274	10,316	10,325	10,527	10,888	11,394	12,177	12,889	13,913	15,052	16,214
F	10,535	10,584	10,621	10,825	11,207	11,715	12,439	13,038	13,873	14,789	15,705
Total	20,809	20,900	20,946	21,352	22,095	23,109	24,616	25,927	27,786	29,841	31,919
Spain											
M	3,548	3,458	3,416	3,420	3,434	3,464	3,343	3,040	2,951	2,928	2,901
F	2,967	2,925	2,913	2,934	2,978	3,024	2,927	2,611	2,513	2,483	2,453
Total	6,515	6,383	6,329	6,354	6,412	6,488	6,270	5,651	5,464	5,411	5,354
Sri Lanka											
M	5,827	6,408	6,730	7,067	7,510	8,000	8,410	8,663	8,668	8,620	8,571
F	5,577	6,097	6,455	6,815	7,287	7,822	8,241	8,474	8,475	8,426	8,374
Total	11,404	12,505	13,185	13,882	14,797	15,822	16,651	17,137	17,143	17,046	16,945
United Kingdom and Ireland											
M	175,141	173,732	172,043	171,058	170,706	170,621	172,484	171,320	169,864	168,533	167,131
F	169,269	167,467	165,273	163,781	162,821	162,151	163,520	161,618	159,479	157,410	155,233
Total	344,410	341,199	337,316	334,839	333,527	332,772	336,004	332,938	329,343	325,943	322,364
United States of America											
M	8,819	8,859	8,825	8,988	9,336	9,882	10,473	11,714	11,659	11,207	10,764
F	8,291	8,441	8,447	8,605	8,967	9,386	9,666	10,567	9,851	8,640	7,417
Total	17,110	17,300	17,272	17,593	18,303	19,268	20,139	22,281	21,510	19,847	18,181
Vietnam											
M	26,407	28,337	29,573	30,936	32,248	33,375	34,067	35,267	35,194	34,780	34,393
F	23,995	26,505	28,074	29,813	31,613	33,178	33,992	35,483	35,746	35,644	35,560
Total	50,402	54,842	57,647	60,749	63,861	66,553	68,059	70,750	70,940	70,424	69,953
Yugoslavia											
M	34,051	34,481	35,043	35,831	36,954	38,262	38,992	39,885	40,511	41,032	41,530
F	30,140	30,663	31,350	32,220	33,545	35,132	36,143	37,255	38,125	38,866	39,563
Total	64,191	65,144	66,393	68,051	70,499	73,394	75,135	77,140	78,636	79,898	81,093

Appendix 2 Places of birth included in this report and names of constituent places

Place of birth	Constituent places (if applicable)
China	People's Republic of China. Does not include Chinese Special Administrative Region of Hong Kong or the Chinese Special Administrative Region of Macau or Taiwan
Egypt	
Fiji	
Germany	
Greece	
Hong Kong and Macau	Chinese Special Administrative Region of Hong Kong Chinese Special Administrative Region of Macau
India	
Indonesia	
Italy	
Korea	North Korea South Korea
Lebanon	
Malaysia and Brunei	Malaysia Brunei
Malta	
Netherlands	
New Zealand	
Philippines	
Poland	
Portugal	
South Africa	
Spain	
Sri Lanka	
United Kingdom and Ireland	England Wales Scotland Northern Ireland Ireland
United States of America	
Vietnam	
Yugoslavia	Croatia Serbia and Montenegro Bosnia and Herzegovina Slovenia The Former Yugoslavian Republic of Macedonia

Appendix 3 Cancer types included in this report and descriptions of grouped types

Cancer type	Constituent cancer types (if applicable) and ICD-O-3 codes
Bladder	C67
Cancer of the brain and central nervous system	Brain C71, C72 Central nervous system C70, C72
Breast	C50
Cancers with an indefinite or unspecified site	Other and ill defined digestive organs C26 Other and ill defined respiratory C39 Retroperitoneum and peritoneum C48 Other and ill defined sites C76 Unknown primary site C80
Cervix	C53
Colorectal	Colon C18 Rectum, rectosigmoid, anus C19-C21
Head and Neck	Tongue C01, C02, Mouth C03-C06 Salivary glands C07, C08, Oropharynx C09, C10, Nasopharynx C11, Hypopharynx C12, C13 Other oral cavity and pharynx C14, Nose, sinuses, etc C30, C31, Larynx C32
Kidney	C64-C66, C68
Leukaemia	Acute lymphoblastic leukaemia M9821 Other lymphoid leukaemias M9820, M9822-M9827, M994 Acute myeloid leukaemia M9861 Other myeloid leukaemia M9860, M9862-8, M987-M988, M9930, M9987 Other specified leukaemias M984, M985, M989-M993 Unspecified leukaemias M980
Liver	C22
Lung	Lung C33 Bronchus C34
Melanoma of the skin	C44 and M872-M879
Non-Hodgkin lymphoma	M959, M967-M972, M974
Ovary	C56, C57.0-7
Pancreas	C25
Prostate	C61
Stomach	C16
Testis	C62
Thyroid	C73
Uterus	Body of Uterus and NOS C54, C55,

Appendix 4**Table A4.1: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for bladder cancer by place of birth, NSW 1991 to 2001**

Place of birth	Cases	Expected	SIR	99% CI
Males				
Vietnam	3	27	0.11	(0.01-0.41)
Philippines	7	17	0.40	(0.12-0.99)
China	43	81	0.53	(0.34-0.77)
Malta	26	36	0.72	(0.41-1.17)
India	22	26	0.85	(0.45-1.43)
Yugoslavia	87	91	0.96	(0.71-1.25)
New Zealand	57	59	0.96	(0.67-1.34)
Egypt	31	32	0.98	(0.58-1.53)
Italy	201	181	1.11	(0.92-1.33)
Greece	99	89	1.12	(0.85-1.44)
Poland	71	59	1.20	(0.86-1.61)
Lebanon	53	42	1.26	(0.86-1.77)
United Kingdom and Ireland	778	596	1.31	(1.19-1.43)
Germany	76	53	1.44	(1.05-1.92)
United States of America	20	13	1.52	(0.79-2.63)
South Africa	25	16	1.57	(0.88-2.57)
Netherlands	84	53	1.59	(1.18-2.09)
Spain	16	8	2.01	(0.95-3.69)
Females				
China	16	29	0.56	(0.26-1.03)
Germany	14	21	0.65	(0.29-1.25)
New Zealand	16	21	0.75	(0.35-1.37)
Yugoslavia	19	25	0.76	(0.39-1.34)
Greece	23	24	0.95	(0.52-1.58)
Italy	46	47	0.99	(0.65-1.43)
Netherlands	15	15	1.03	(0.47-1.94)
Poland	16	15	1.04	(0.49-1.92)
Malta	11	10	1.05	(0.41-2.18)
United Kingdom and Ireland	221	197	1.12	(0.94-1.33)
Egypt	11	10	1.13	(0.44-2.33)
Lebanon	15	11	1.32	(0.61-2.48)

Table A4.2: Cases, standardised incidence ratios compared to Australian-born females and 99% confidence intervals for breast cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Females				
Korea	42	101	0.41	(0.27-0.61)
Vietnam	149	287	0.52	(0.42-0.64)
China	296	538	0.55	(0.47-0.64)
Yugoslavia	365	606	0.60	(0.52-0.69)
Sri Lanka	57	86	0.66	(0.46-0.93)
Poland	145	214	0.68	(0.54-0.84)
Lebanon	237	316	0.75	(0.63-0.89)
Greece	429	541	0.79	(0.70-0.90)
Italy	639	799	0.80	(0.72-0.88)
Malta	186	231	0.80	(0.66-0.97)
India	166	190	0.87	(0.71-1.06)
Fiji	96	105	0.91	(0.69-1.18)
Philippines	288	314	0.92	(0.78-1.07)
Indonesia	77	82	0.94	(0.69-1.25)
Malaysia and Brunei	113	118	0.96	(0.74-1.22)
Netherlands	249	251	0.99	(0.84-1.17)
United Kingdom and Ireland	3,065	3,080	1.00	(0.95-1.04)
Germany	395	395	1.00	(0.88-1.14)
New Zealand	519	500	1.04	(0.92-1.16)
South Africa	146	139	1.05	(0.84-1.30)
Portugal	67	63	1.06	(0.75-1.44)
Hong Kong and Macau	130	118	1.10	(0.87-1.37)
Egypt	201	182	1.11	(0.92-1.32)
United States of America	107	87	1.23	(0.95-1.57)
Spain	68	50	1.36	(0.97-1.85)

Table A4.3: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for cancers of the brain and central nervous system by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Vietnam	3	21	0.14	(0.02-0.52)
China	17	38	0.45	(0.22-0.82)
Philippines	8	14	0.58	(0.19-1.35)
Egypt	11	14	0.81	(0.32-1.69)
New Zealand	32	38	0.85	(0.51-1.32)
India	13	15	0.87	(0.37-1.71)
Lebanon	26	27	0.95	(0.54-1.55)
United Kingdom and Ireland	225	230	0.98	(0.82-1.16)
Malta	17	17	1.00	(0.49-1.82)
Italy	70	67	1.04	(0.75-1.40)
Yugoslavia	49	46	1.06	(0.71-1.52)
Germany	31	25	1.25	(0.75-1.96)
Greece	48	38	1.27	(0.85-1.82)
Netherlands	27	20	1.33	(0.76-2.14)
Poland	29	17	1.68	(0.99-2.67)
Females				
Philippines	6	16	0.38	(0.10-0.98)
China	11	28	0.39	(0.15-0.81)
Poland	6	12	0.51	(0.13-1.34)
New Zealand	14	26	0.53	(0.24-1.02)
Lebanon	10	16	0.62	(0.23-1.33)
Vietnam	10	16	0.64	(0.24-1.37)
Germany	18	19	0.94	(0.47-1.68)
Greece	24	24	1.00	(0.55-1.66)
United Kingdom and Ireland	158	154	1.02	(0.83-1.25)
Yugoslavia	29	28	1.03	(0.61-1.64)
Italy	46	39	1.17	(0.78-1.70)
Egypt	11	9	1.23	(0.48-2.55)
Netherlands	20	12	1.65	(0.85-2.86)

Table A4.4: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for cancers with an indefinite site by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Sri Lanka	4	13	0.31	(0.05-0.97)
Egypt	21	40	0.52	(0.27-0.89)
Malaysia and Brunei	6	11	0.52	(0.13-1.36)
Lebanon	33	57	0.58	(0.35-0.89)
India	20	34	0.59	(0.30-1.01)
Vietnam	22	36	0.60	(0.32-1.02)
China	66	103	0.64	(0.45-0.87)
South Africa	14	21	0.66	(0.29-1.27)
United States of America	12	18	0.69	(0.28-1.38)
Indonesia	9	13	0.70	(0.24-1.56)
Italy	173	228	0.76	(0.62-0.92)
Philippines	18	24	0.76	(0.38-1.36)
Korea	11	14	0.78	(0.31-1.61)
Fiji	10	12	0.82	(0.30-1.75)
Germany	56	68	0.82	(0.57-1.15)
United Kingdom and Ireland	631	754	0.84	(0.75-0.93)
New Zealand	67	80	0.84	(0.60-1.14)
Greece	99	114	0.87	(0.66-1.12)
Yugoslavia	104	119	0.87	(0.67-1.12)
Malta	43	47	0.92	(0.60-1.34)
Netherlands	67	66	1.01	(0.72-1.37)
Poland	75	72	1.05	(0.76-1.40)
Portugal	11	10	1.13	(0.44-2.34)
Hong Kong and Macau	14	12	1.15	(0.51-2.21)
Spain	14	10	1.34	(0.60-2.58)
Females				
China	49	88	0.56	(0.37-0.80)
Philippines	23	32	0.72	(0.39-1.20)
Sri Lanka	9	12	0.78	(0.27-1.73)
Malta	26	32	0.82	(0.47-1.34)
Greece	62	75	0.83	(0.58-1.14)
Vietnam	26	31	0.83	(0.47-1.35)
Italy	126	140	0.90	(0.71-1.13)
Germany	58	64	0.90	(0.63-1.26)
Lebanon	32	35	0.91	(0.55-1.41)
South Africa	18	20	0.91	(0.45-1.63)
Yugoslavia	71	76	0.94	(0.68-1.27)
United Kingdom and Ireland	612	628	0.97	(0.88-1.08)
Poland	44	45	0.98	(0.64-1.43)
Egypt	29	29	0.99	(0.58-1.57)
Netherlands	44	44	1.00	(0.66-1.46)
Korea	11	11	1.01	(0.40-2.08)
New Zealand	78	71	1.11	(0.81-1.47)
India	30	27	1.11	(0.66-1.74)
Indonesia	14	10	1.44	(0.64-2.77)
Hong Kong and Macau	16	10	1.54	(0.73-2.83)
Fiji	17	11	1.55	(0.75-2.80)

Table A4.5: Cases, standardised incidence ratios compared to Australian-born females and 99% confidence intervals for cervical cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Females				
South Africa	5	12	0.41	(0.09-1.15)
Italy	29	53	0.55	(0.32-0.86)
Malta	9	16	0.56	(0.19-1.24)
India	10	17	0.60	(0.22-1.29)
Lebanon	19	31	0.62	(0.31-1.09)
Greece	26	35	0.74	(0.42-1.19)
Hong Kong and Macau	12	15	0.79	(0.32-1.59)
Malaysia and Brunei	10	12	0.85	(0.32-1.81)
Netherlands	15	17	0.86	(0.40-1.62)
Germany	26	28	0.94	(0.53-1.53)
United Kingdom and Ireland	254	232	1.09	(0.93-1.28)
Egypt	15	13	1.11	(0.51-2.09)
Poland	19	15	1.23	(0.62-2.16)
United States of America	11	9	1.26	(0.49-2.61)
Yugoslavia	58	46	1.27	(0.88-1.76)
China	64	45	1.42	(1.01-1.95)
New Zealand	73	49	1.50	(1.09-2.01)
Korea	17	10	1.72	(0.83-3.11)
Vietnam	53	30	1.76	(1.20-2.48)
Philippines	58	32	1.80	(1.25-2.50)
Indonesia	17	8	2.06	(1.00-3.74)
Fiji	27	11	2.39	(1.37-3.86)

Table A4.6: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for colorectal cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Vietnam	49	129	0.38	(0.25-0.54)
India	47	118	0.40	(0.27-0.58)
Sri Lanka	19	46	0.41	(0.21-0.73)
South Africa	32	72	0.44	(0.27-0.69)
Lebanon	92	207	0.44	(0.33-0.58)
Korea	27	53	0.51	(0.29-0.83)
Indonesia	24	45	0.53	(0.30-0.89)
Egypt	74	138	0.54	(0.39-0.72)
Malaysia and Brunei	23	43	0.54	(0.29-0.90)
Fiji	24	44	0.54	(0.30-0.90)
Greece	244	413	0.59	(0.50-0.69)
China	204	345	0.59	(0.49-0.71)
Malta	100	169	0.59	(0.45-0.76)
Philippines	49	81	0.60	(0.40-0.86)
Netherlands	159	226	0.70	(0.57-0.86)
Yugoslavia	319	439	0.73	(0.63-0.84)
United Kingdom and Ireland	1,909	2,426	0.79	(0.74-0.83)
United States of America	48	61	0.79	(0.53-1.14)
Italy	625	781	0.80	(0.72-0.89)
Germany	207	244	0.85	(0.70-1.01)
Portugal	35	37	0.95	(0.59-1.45)
Spain	39	39	1.00	(0.64-1.50)
Poland	216	214	1.01	(0.84-1.20)
New Zealand	273	269	1.02	(0.86-1.19)
Hong Kong and Macau	49	43	1.13	(0.76-1.61)
Females				
Lebanon	47	121	0.39	(0.26-0.56)
Vietnam	44	105	0.42	(0.27-0.61)
Philippines	49	106	0.46	(0.31-0.66)
Sri Lanka	17	37	0.46	(0.22-0.84)
India	41	86	0.48	(0.31-0.70)
Egypt	51	93	0.55	(0.37-0.78)
South Africa	35	60	0.58	(0.36-0.89)
Korea	22	37	0.60	(0.32-1.01)
Fiji	23	37	0.62	(0.34-1.04)
Yugoslavia	164	262	0.62	(0.51-0.76)
Greece	162	255	0.64	(0.51-0.78)
Malta	68	106	0.64	(0.46-0.87)
China	175	269	0.65	(0.53-0.79)
Indonesia	21	32	0.66	(0.35-1.12)
Italy	306	443	0.69	(0.59-0.80)
Malaysia and Brunei	27	38	0.72	(0.41-1.16)
Netherlands	100	136	0.74	(0.56-0.95)
Poland	104	133	0.78	(0.60-1.00)
United Kingdom and Ireland	1,457	1,781	0.82	(0.76-0.87)
Germany	189	203	0.93	(0.77-1.12)
Spain	23	23	1.01	(0.55-1.69)
New Zealand	219	211	1.04	(0.86-1.23)
Portugal	25	24	1.04	(0.58-1.70)
Hong Kong and Macau	38	35	1.10	(0.69-1.65)
United States of America	37	31	1.20	(0.75-1.81)

Table A4.7: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for head and neck cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Korea	3	19	0.16	(0.02-0.59)
Greece	46	134	0.34	(0.23-0.50)
Malta	23	55	0.42	(0.23-0.70)
Sri Lanka	7	15	0.45	(0.13-1.11)
Egypt	20	43	0.46	(0.24-0.80)
India	19	38	0.50	(0.25-0.87)
Netherlands	36	69	0.52	(0.32-0.79)
South Africa	13	24	0.55	(0.23-1.07)
Lebanon	42	71	0.59	(0.38-0.87)
Indonesia	10	15	0.66	(0.24-1.40)
Yugoslavia	101	147	0.69	(0.52-0.88)
Italy	166	240	0.69	(0.56-0.84)
New Zealand	61	88	0.69	(0.49-0.96)
Germany	56	79	0.71	(0.49-0.99)
Philippines	21	28	0.75	(0.40-1.29)
Portugal	10	13	0.77	(0.29-1.65)
Poland	45	57	0.78	(0.51-1.14)
United States of America	16	20	0.80	(0.38-1.48)
United Kingdom and Ireland	586	718	0.82	(0.73-0.91)
China	86	105	0.82	(0.61-1.07)
Spain	12	13	0.91	(0.38-1.84)
Fiji	15	16	0.96	(0.44-1.80)
Vietnam	50	45	1.12	(0.75-1.60)
Malaysia and Brunei	19	16	1.22	(0.62-2.14)
Hong Kong and Macau	39	16	2.40	(1.53-3.58)
Females				
India	3	11	0.27	(0.03-0.99)
Yugoslavia	12	34	0.35	(0.15-0.71)
Greece	16	32	0.50	(0.24-0.92)
Netherlands	10	16	0.61	(0.23-1.30)
Egypt	7	11	0.61	(0.18-1.49)
Poland	10	16	0.64	(0.24-1.37)
Italy	35	53	0.66	(0.41-1.00)
Germany	20	25	0.80	(0.41-1.38)
Malta	11	13	0.82	(0.32-1.70)
United Kingdom and Ireland	199	208	0.96	(0.79-1.15)
New Zealand	32	28	1.15	(0.69-1.79)
Lebanon	20	17	1.20	(0.62-2.08)
China	45	33	1.35	(0.89-1.96)
Vietnam	22	15	1.47	(0.79-2.50)
Philippines	24	15	1.58	(0.87-2.62)
Hong Kong and Macau	12	5	2.25	(0.93-4.54)
Malaysia and Brunei	17	6	3.08	(1.49-5.57)

Table A4.8: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for kidney cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Vietnam	11	30	0.37	(0.14-0.76)
China	29	72	0.41	(0.24-0.64)
Yugoslavia	48	91	0.53	(0.35-0.76)
India	15	25	0.59	(0.27-1.11)
Korea	7	12	0.59	(0.17-1.45)
United States of America	8	13	0.60	(0.19-1.40)
Philippines	12	19	0.62	(0.26-1.26)
New Zealand	41	59	0.69	(0.45-1.02)
Netherlands	31	45	0.69	(0.41-1.08)
South Africa	12	16	0.76	(0.31-1.53)
United Kingdom and Ireland	410	482	0.85	(0.75-0.96)
Italy	136	152	0.89	(0.71-1.11)
Malta	32	35	0.93	(0.56-1.44)
Lebanon	42	45	0.93	(0.60-1.37)
Egypt	26	28	0.93	(0.53-1.51)
Greece	86	82	1.05	(0.78-1.37)
Germany	55	49	1.11	(0.76-1.56)
Portugal	11	8	1.37	(0.54-2.83)
Spain	12	8	1.51	(0.62-3.05)
Poland	68	41	1.65	(1.18-2.24)
Females				
India	7	15	0.46	(0.13-1.13)
New Zealand	20	37	0.55	(0.28-0.95)
Egypt	9	16	0.55	(0.19-1.23)
Vietnam	11	19	0.57	(0.23-1.19)
Yugoslavia	27	45	0.60	(0.34-0.96)
Philippines	12	20	0.61	(0.25-1.23)
Italy	47	76	0.62	(0.41-0.89)
China	29	47	0.62	(0.36-0.99)
Malta	14	18	0.76	(0.34-1.47)
Lebanon	17	22	0.79	(0.38-1.43)
Poland	20	24	0.84	(0.43-1.45)
United Kingdom and Ireland	254	296	0.86	(0.73-1.01)
Greece	37	42	0.87	(0.55-1.31)
Germany	37	36	1.04	(0.65-1.57)
Netherlands	26	24	1.10	(0.62-1.79)

Table A4.9: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for leukaemia by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Korea	3	11	0.27	(0.03-1.00)
China	33	65	0.51	(0.31-0.79)
Hong Kong and Macau	7	12	0.59	(0.17-1.45)
Egypt	15	24	0.63	(0.29-1.18)
Vietnam	21	29	0.73	(0.39-1.26)
United Kingdom and Ireland	335	438	0.77	(0.66-0.88)
Malta	22	28	0.79	(0.42-1.34)
Greece	52	65	0.80	(0.54-1.13)
New Zealand	46	57	0.81	(0.54-1.17)
Philippines	16	19	0.82	(0.39-1.52)
Lebanon	32	39	0.82	(0.50-1.28)
Yugoslavia	63	73	0.86	(0.61-1.19)
Germany	36	41	0.89	(0.55-1.35)
India	21	23	0.90	(0.48-1.54)
Netherlands	35	38	0.92	(0.57-1.40)
Italy	131	128	1.02	(0.81-1.28)
Poland	41	40	1.03	(0.66-1.51)
South Africa	17	15	1.15	(0.56-2.07)
Indonesia	13	10	1.33	(0.57-2.61)
United States of America	19	13	1.52	(0.77-2.67)
Malaysia and Brunei	19	9	2.01	(1.02-3.53)
Females				
Vietnam	11	19	0.59	(0.23-1.22)
India	10	14	0.72	(0.27-1.55)
Poland	15	19	0.78	(0.36-1.46)
Yugoslavia	29	36	0.81	(0.48-1.28)
China	35	42	0.84	(0.52-1.28)
Germany	24	28	0.85	(0.47-1.40)
Greece	29	33	0.89	(0.52-1.41)
Egypt	12	13	0.91	(0.37-1.82)
Malta	13	14	0.92	(0.39-1.80)
Netherlands	18	19	0.94	(0.47-1.68)
United Kingdom and Ireland	268	273	0.98	(0.83-1.15)
New Zealand	41	38	1.08	(0.69-1.59)
Philippines	22	19	1.13	(0.61-1.91)
Italy	68	59	1.15	(0.82-1.55)
Lebanon	30	19	1.55	(0.92-2.44)
Fiji	11	7	1.59	(0.62-3.29)

Table A4.10: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for liver cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Netherlands	6	12	0.49	(0.12-1.27)
Lebanon	6	11	0.54	(0.14-1.40)
Poland	9	12	0.77	(0.27-1.70)
New Zealand	11	14	0.77	(0.30-1.60)
United Kingdom and Ireland	103	128	0.80	(0.61-1.03)
Germany	14	13	1.07	(0.48-2.06)
Greece	26	22	1.16	(0.66-1.89)
Yugoslavia	37	24	1.56	(0.98-2.35)
Italy	87	43	2.01	(1.50-2.64)
Philippines	14	5	3.06	(1.36-5.86)
Egypt	25	7	3.36	(1.88-5.51)
China	119	19	6.18	(4.82-7.80)
Indonesia	16	2	6.45	(3.05-11.88)
Korea	25	3	8.71	(4.88-14.29)
Hong Kong and Macau	22	2	9.34	(5.00-15.80)
Vietnam	86	7	11.66	(8.68-15.31)
Females				
United Kingdom and Ireland	38	39	0.97	(0.61-1.46)
Italy	29	9	3.29	(1.93-5.22)
China	38	6	6.31	(3.99-9.46)
Vietnam	32	2	13.13	(7.92-20.38)

Table A4.11: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for lung cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Sri Lanka	6	35	0.17	(0.04-0.45)
Korea	17	39	0.44	(0.21-0.79)
India	41	92	0.45	(0.29-0.66)
Fiji	16	33	0.49	(0.23-0.90)
South Africa	28	55	0.51	(0.29-0.81)
Egypt	59	113	0.52	(0.36-0.72)
Malaysia and Brunei	22	31	0.72	(0.39-1.22)
Lebanon	115	158	0.73	(0.57-0.92)
China	217	279	0.78	(0.65-0.92)
Indonesia	30	35	0.85	(0.51-1.34)
Hong Kong and Macau	27	31	0.86	(0.49-1.38)
New Zealand	180	205	0.88	(0.72-1.06)
Greece	299	333	0.90	(0.77-1.04)
Portugal	25	27	0.91	(0.51-1.50)
United States of America	44	47	0.94	(0.61-1.36)
Italy	627	658	0.95	(0.86-1.06)
Vietnam	95	97	0.98	(0.74-1.27)
Poland	189	192	0.99	(0.81-1.19)
Yugoslavia	353	345	1.02	(0.89-1.17)
Philippines	63	61	1.03	(0.73-1.42)
Germany	216	195	1.11	(0.92-1.31)
United Kingdom and Ireland	2,385	2,008	1.19	(1.13-1.25)
Spain	39	31	1.25	(0.80-1.87)
Netherlands	245	190	1.29	(1.09-1.52)
Malta	185	134	1.38	(1.13-1.66)
Females				
Spain	1	11	0.09	(0.00-0.66)
Greece	35	123	0.28	(0.18-0.43)
Sri Lanka	5	18	0.28	(0.06-0.80)
Portugal	4	12	0.34	(0.06-1.07)
Yugoslavia	56	130	0.43	(0.30-0.60)
Italy	94	214	0.44	(0.33-0.57)
Egypt	20	45	0.44	(0.23-0.77)
Lebanon	31	59	0.52	(0.31-0.82)
Malaysia and Brunei	11	19	0.59	(0.23-1.22)
Vietnam	34	52	0.66	(0.40-1.01)
Korea	12	18	0.68	(0.28-1.36)
Malta	36	52	0.69	(0.43-1.04)
Philippines	37	53	0.70	(0.44-1.06)
South Africa	24	28	0.86	(0.47-1.42)
India	37	41	0.89	(0.56-1.35)
Indonesia	15	16	0.95	(0.44-1.79)
Fiji	17	18	0.95	(0.46-1.73)
China	125	128	0.98	(0.77-1.22)
Poland	66	65	1.01	(0.72-1.38)
Germany	107	100	1.07	(0.82-1.37)
United States of America	16	14	1.11	(0.53-2.05)
New Zealand	123	96	1.28	(1.00-1.61)
Netherlands	85	65	1.30	(0.97-1.71)
Hong Kong and Macau	22	16	1.34	(0.72-2.27)
United Kingdom and Ireland	1,162	793	1.47	(1.36-1.58)

Table A4.12: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for melanoma of the skin by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Philippines	1	63	0.02	(0.00-0.12)
Korea	1	37	0.03	(0.00-0.20)
Malaysia and Brunei	1	33	0.03	(0.00-0.22)
Sri Lanka	1	31	0.03	(0.00-0.24)
Lebanon	5	137	0.04	(0.01-0.10)
Vietnam	4	99	0.04	(0.01-0.13)
China	14	205	0.07	(0.03-0.13)
India	6	76	0.08	(0.02-0.21)
Hong Kong and Macau	3	37	0.08	(0.01-0.29)
Portugal	2	24	0.08	(0.00-0.39)
Malta	8	94	0.09	(0.03-0.20)
Greece	22	215	0.10	(0.05-0.17)
Fiji	4	33	0.12	(0.02-0.38)
Indonesia	4	32	0.13	(0.02-0.40)
Egypt	12	76	0.16	(0.06-0.32)
Italy	63	397	0.16	(0.11-0.22)
Yugoslavia	40	249	0.16	(0.10-0.24)
Spain	6	22	0.28	(0.07-0.72)
Poland	38	110	0.35	(0.22-0.52)
United Kingdom and Ireland	587	1,326	0.44	(0.40-0.49)
Netherlands	58	119	0.49	(0.34-0.68)
Germany	73	135	0.54	(0.39-0.73)
United States of America	23	40	0.57	(0.31-0.95)
South Africa	33	48	0.69	(0.42-1.06)
New Zealand	143	184	0.78	(0.62-0.96)
Females				
Lebanon	2	81	0.02	(0.00-0.11)
Vietnam	2	78	0.03	(0.00-0.12)
Philippines	3	81	0.04	(0.00-0.13)
Sri Lanka	1	21	0.05	(0.00-0.35)
Hong Kong and Macau	2	34	0.06	(0.00-0.27)
Egypt	3	42	0.07	(0.01-0.26)
China	10	134	0.07	(0.03-0.16)
India	4	48	0.08	(0.01-0.26)
Fiji	3	29	0.10	(0.01-0.38)
Malta	6	50	0.12	(0.03-0.31)
Malaysia and Brunei	4	30	0.13	(0.02-0.42)
Indonesia	3	22	0.14	(0.02-0.49)
Yugoslavia	21	136	0.15	(0.08-0.26)
Greece	18	115	0.16	(0.08-0.28)
Spain	3	11	0.27	(0.03-0.98)
Italy	50	177	0.28	(0.19-0.40)
Poland	20	51	0.40	(0.20-0.68)
Germany	41	88	0.46	(0.30-0.69)
United Kingdom and Ireland	371	741	0.50	(0.44-0.57)
United States of America	12	22	0.54	(0.22-1.08)
South Africa	19	35	0.55	(0.28-0.96)
Netherlands	35	56	0.62	(0.39-0.95)
New Zealand	130	132	0.98	(0.77-1.23)

Table A4.13: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for non-Hodgkin lymphoma by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Korea	5	17	0.30	(0.06-0.84)
India	14	34	0.41	(0.18-0.78)
Fiji	8	15	0.52	(0.17-1.20)
Philippines	16	29	0.55	(0.26-1.01)
Sri Lanka	8	14	0.57	(0.18-1.31)
China	57	93	0.61	(0.42-0.85)
Yugoslavia	69	111	0.62	(0.45-0.85)
United States of America	12	18	0.65	(0.27-1.31)
Hong Kong and Macau	12	18	0.66	(0.27-1.32)
Lebanon	42	62	0.68	(0.44-1.00)
South Africa	16	22	0.73	(0.34-1.34)
Germany	46	60	0.77	(0.51-1.11)
Poland	40	50	0.79	(0.51-1.18)
Vietnam	37	45	0.82	(0.51-1.23)
Netherlands	44	53	0.83	(0.54-1.21)
New Zealand	74	85	0.87	(0.63-1.17)
United Kingdom and Ireland	537	604	0.89	(0.79-0.99)
Malaysia and Brunei	14	15	0.92	(0.41-1.76)
Italy	168	178	0.94	(0.77-1.15)
Greece	92	96	0.96	(0.72-1.25)
Malta	41	42	0.98	(0.63-1.45)
Egypt	34	34	0.99	(0.61-1.51)
Indonesia	21	15	1.44	(0.76-2.46)
Spain	18	10	1.85	(0.92-3.30)
Females				
Korea	1	11	0.09	(0.00-0.67)
Fiji	3	11	0.26	(0.03-0.96)
Vietnam	15	32	0.47	(0.22-0.88)
India	13	24	0.55	(0.23-1.07)
China	42	72	0.58	(0.38-0.85)
Yugoslavia	48	70	0.69	(0.46-0.99)
Hong Kong and Macau	9	12	0.74	(0.26-1.64)
Egypt	19	24	0.78	(0.40-1.37)
Philippines	26	33	0.79	(0.45-1.28)
Germany	42	53	0.80	(0.52-1.18)
South Africa	14	17	0.83	(0.37-1.58)
Netherlands	29	35	0.83	(0.49-1.31)
United Kingdom and Ireland	388	459	0.85	(0.74-0.96)
Italy	98	112	0.88	(0.67-1.13)
Greece	58	65	0.89	(0.62-1.24)
New Zealand	57	61	0.94	(0.65-1.30)
Poland	33	34	0.97	(0.59-1.49)
Lebanon	37	35	1.06	(0.66-1.59)
Malaysia and Brunei	14	12	1.19	(0.53-2.28)
Malta	45	28	1.62	(1.07-2.36)
Indonesia	16	10	1.67	(0.79-3.07)

Table A4.14: Cases, standardised incidence ratios compared to Australian-born females and 99% confidence intervals for ovarian cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Females				
Lebanon	18	29	0.62	(0.31-1.11)
Vietnam	17	26	0.65	(0.31-1.18)
China	41	54	0.76	(0.49-1.12)
Greece	43	54	0.80	(0.52-1.17)
Italy	70	85	0.82	(0.59-1.11)
Yugoslavia	56	58	0.97	(0.67-1.35)
New Zealand	47	47	0.99	(0.66-1.43)
India	19	19	1.03	(0.52-1.80)
Malta	24	22	1.07	(0.59-1.77)
Netherlands	29	27	1.09	(0.64-1.73)
Philippines	31	27	1.15	(0.69-1.79)
United Kingdom and Ireland	386	331	1.17	(1.02-1.33)
Germany	49	41	1.20	(0.81-1.72)
Egypt	23	19	1.23	(0.67-2.06)
Malaysia and Brunei	13	10	1.28	(0.55-2.52)
South Africa	17	13	1.28	(0.62-2.33)
Fiji	13	10	1.36	(0.59-2.67)
Hong Kong and Macau	15	10	1.47	(0.68-2.77)
Indonesia	12	8	1.54	(0.63-3.09)
Poland	42	24	1.73	(1.12-2.54)
United States of America	17	8	2.20	(1.07-3.99)

Table A4.15: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for pancreatic cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Netherlands	21	30	0.71	(0.38-1.22)
New Zealand	25	34	0.73	(0.41-1.20)
India	11	15	0.74	(0.29-1.53)
Egypt	15	18	0.84	(0.39-1.58)
Italy	85	100	0.85	(0.63-1.11)
China	39	45	0.86	(0.55-1.29)
Yugoslavia	48	52	0.92	(0.61-1.32)
United Kingdom and Ireland	303	329	0.92	(0.79-1.07)
Lebanon	23	25	0.92	(0.50-1.55)
Germany	32	30	1.05	(0.64-1.64)
Vietnam	18	16	1.14	(0.56-2.03)
Greece	65	50	1.30	(0.92-1.78)
Poland	42	32	1.33	(0.86-1.95)
Malta	28	21	1.34	(0.78-2.15)
Females				
Vietnam	11	15	0.74	(0.29-1.54)
Greece	28	37	0.76	(0.44-1.22)
Philippines	12	15	0.81	(0.33-1.64)
Yugoslavia	32	37	0.86	(0.52-1.33)
Netherlands	19	22	0.86	(0.44-1.51)
China	38	43	0.89	(0.56-1.33)
United Kingdom and Ireland	295	302	0.98	(0.84-1.13)
India	13	13	0.99	(0.42-1.94)
Italy	70	70	0.99	(0.71-1.34)
Egypt	15	15	1.02	(0.47-1.91)
Germany	33	32	1.02	(0.62-1.58)
Lebanon	18	17	1.07	(0.53-1.90)
Poland	25	23	1.09	(0.61-1.78)
New Zealand	37	32	1.14	(0.71-1.72)
Malta	21	16	1.34	(0.71-2.29)

Table A4.16: Cases, standardised incidence ratios compared to Australian-born males and 99% confidence intervals for prostate cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Korea	15	69	0.22	(0.10-0.41)
Vietnam	42	175	0.24	(0.16-0.35)
China	177	550	0.32	(0.26-0.39)
Philippines	53	112	0.48	(0.32-0.67)
Sri Lanka	32	65	0.49	(0.30-0.77)
Yugoslavia	326	642	0.51	(0.44-0.58)
India	92	175	0.53	(0.40-0.69)
Lebanon	159	286	0.56	(0.45-0.68)
Greece	353	635	0.56	(0.48-0.64)
Malta	145	254	0.57	(0.46-0.70)
Italy	845	1,306	0.65	(0.59-0.71)
Egypt	150	223	0.67	(0.54-0.83)
Indonesia	44	65	0.67	(0.44-0.98)
Fiji	40	59	0.68	(0.44-1.01)
Hong Kong and Macau	40	56	0.72	(0.46-1.07)
Portugal	35	49	0.72	(0.44-1.10)
Poland	299	415	0.72	(0.62-0.83)
Netherlands	287	378	0.76	(0.65-0.88)
United Kingdom and Ireland	3,231	4,139	0.78	(0.75-0.82)
Malaysia and Brunei	41	52	0.78	(0.50-1.15)
South Africa	82	105	0.78	(0.58-1.04)
Spain	45	57	0.79	(0.52-1.14)
New Zealand	340	394	0.86	(0.75-0.99)
Germany	330	372	0.89	(0.77-1.02)
United States of America	86	90	0.95	(0.71-1.25)

Table A4.17: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for stomach cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Philippines	6	13	0.45	(0.11-1.17)
India	14	19	0.74	(0.33-1.43)
Lebanon	25	32	0.79	(0.44-1.29)
Egypt	18	22	0.81	(0.40-1.44)
Netherlands	35	37	0.96	(0.59-1.46)
Malta	26	26	1.00	(0.57-1.62)
New Zealand	46	44	1.05	(0.69-1.51)
South Africa	14	12	1.19	(0.53-2.28)
United Kingdom and Ireland	562	411	1.37	(1.22-1.52)
Italy	169	123	1.37	(1.11-1.66)
Greece	99	62	1.60	(1.22-2.07)
China	92	56	1.64	(1.23-2.13)
Vietnam	35	20	1.72	(1.06-2.62)
Poland	70	39	1.78	(1.28-2.40)
Hong Kong and Macau	13	7	1.84	(0.79-3.61)
Germany	72	38	1.90	(1.37-2.55)
Spain	11	6	1.92	(0.75-3.97)
Yugoslavia	130	65	1.99	(1.57-2.49)
Korea	37	8	4.71	(2.95-7.10)
Females				
Netherlands	12	14	0.87	(0.36-1.74)
New Zealand	22	22	0.99	(0.53-1.68)
Philippines	11	10	1.06	(0.42-2.21)
United Kingdom and Ireland	257	196	1.31	(1.11-1.54)
Germany	28	20	1.39	(0.80-2.22)
Italy	70	43	1.61	(1.16-2.18)
Lebanon	18	11	1.62	(0.81-2.89)
Malta	17	10	1.73	(0.84-3.13)
South Africa	13	6	2.12	(0.91-4.15)
China	61	28	2.21	(1.55-3.05)
Greece	51	23	2.25	(1.52-3.20)
Poland	32	14	2.25	(1.36-3.50)
Vietnam	25	10	2.52	(1.41-4.13)
Yugoslavia	60	23	2.60	(1.81-3.59)
Malaysia and Brunei	12	3	3.54	(1.46-7.12)
Korea	18	3	5.32	(2.64-9.48)

Table A4.18: Cases, standardised incidence ratios compared to Australian-born males and 99% confidence intervals for testicular cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Vietnam	2	34	0.06	(0.00-0.27)
Hong Kong and Macau	1	15	0.07	(0.00-0.49)
China	6	35	0.17	(0.04-0.45)
India	3	17	0.18	(0.02-0.65)
Philippines	4	19	0.21	(0.04-0.66)
Italy	8	20	0.39	(0.13-0.91)
Greece	6	13	0.46	(0.12-1.20)
Yugoslavia	14	28	0.50	(0.22-0.96)
Lebanon	22	29	0.75	(0.40-1.28)
United Kingdom and Ireland	158	129	1.22	(0.99-1.50)
New Zealand	72	47	1.53	(1.11-2.06)
Germany	17	11	1.58	(0.76-2.85)

Table A4.19: Cases, standardised incidence ratios compared to Australian-born males and females and 99% confidence intervals for thyroid cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
New Zealand	8	14	0.57	(0.18-1.33)
United Kingdom and Ireland	45	69	0.65	(0.43-0.95)
Yugoslavia	14	15	0.93	(0.42-1.79)
China	19	13	1.45	(0.74-2.55)
Italy	28	19	1.51	(0.88-2.42)
Greece	24	11	2.17	(1.20-3.59)
Lebanon	24	10	2.40	(1.32-3.97)
Philippines	14	5	2.60	(1.16-4.98)
Females				
United Kingdom and Ireland	125	156	0.80	(0.63-1.00)
New Zealand	34	41	0.82	(0.50-1.26)
Germany	16	18	0.88	(0.42-1.63)
China	40	37	1.09	(0.70-1.61)
India	17	14	1.24	(0.60-2.25)
Yugoslavia	43	34	1.26	(0.82-1.84)
Poland	14	10	1.45	(0.64-2.78)
Malaysia and Brunei	15	10	1.46	(0.67-2.74)
Italy	53	33	1.60	(1.09-2.25)
Fiji	17	10	1.70	(0.82-3.08)
Sri Lanka	11	6	1.71	(0.67-3.55)
Indonesia	13	7	1.73	(0.74-3.40)
Hong Kong and Macau	24	13	1.84	(1.02-3.05)
Vietnam	53	28	1.92	(1.31-2.71)
Korea	18	9	1.93	(0.96-3.44)
Greece	47	24	1.99	(1.32-2.86)
Lebanon	56	25	2.20	(1.52-3.08)
Philippines	83	28	2.97	(2.20-3.92)
Portugal	14	4	3.17	(1.41-6.07)

Table A4.20: Cases, standardised incidence ratios compared to Australian-born females and 99% confidence intervals for uterine cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Females				
China	37	65	0.57	(0.36-0.86)
Lebanon	20	33	0.61	(0.31-1.05)
Vietnam	18	28	0.63	(0.31-1.13)
South Africa	11	15	0.73	(0.29-1.51)
Netherlands	25	33	0.76	(0.43-1.25)
Yugoslavia	62	71	0.87	(0.61-1.20)
United Kingdom and Ireland	367	401	0.92	(0.80-1.05)
Italy	103	108	0.95	(0.73-1.22)
Germany	51	50	1.01	(0.68-1.44)
New Zealand	56	53	1.06	(0.73-1.48)
Greece	72	67	1.07	(0.77-1.44)
Malta	32	28	1.16	(0.70-1.79)
Malaysia and Brunei	13	11	1.19	(0.51-2.34)
Philippines	36	29	1.23	(0.76-1.86)
Egypt	31	23	1.35	(0.81-2.11)
India	32	22	1.46	(0.88-2.27)
Poland	46	30	1.52	(1.01-2.20)
Fiji	17	10	1.66	(0.80-3.00)
Hong Kong and Macau	18	10	1.85	(0.92-3.29)

Appendix 5**Table A5.1: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for bladder cancer by place of birth, NSW 1991 to 2001**

Place of birth	Cases	Expected	SIR	99% CI
Males				
Vietnam	3	29	0.10	(0.01-0.38)
Egypt	31	112	0.28	(0.17-0.43)
Malta	26	79	0.33	(0.19-0.54)
Italy	201	418	0.48	(0.40-0.58)
Portugal	7	13	0.52	(0.15-1.28)
Greece	99	171	0.58	(0.44-0.75)
Hong Kong and Macau	9	12	0.74	(0.26-1.64)
Yugoslavia	87	112	0.77	(0.58-1.01)
Spain	16	19	0.84	(0.40-1.55)
Lebanon	53	61	0.87	(0.59-1.23)
New Zealand	57	64	0.90	(0.62-1.25)
United States of America	20	22	0.91	(0.47-1.58)
Poland	71	77	0.92	(0.66-1.24)
Germany	76	81	0.94	(0.69-1.26)
Netherlands	84	70	1.20	(0.89-1.59)
United Kingdom and Ireland	778	590	1.32	(1.20-1.44)
China	43	25	1.71	(1.11-2.51)
South Africa	25	13	1.96	(1.10-3.21)
India	22	8	2.83	(1.52-4.79)
Females				
Egypt	11	20	0.56	(0.22-1.16)
Germany	14	25	0.57	(0.25-1.09)
New Zealand	16	27	0.60	(0.28-1.10)
United Kingdom and Ireland	221	310	0.71	(0.60-0.85)
Yugoslavia	19	27	0.72	(0.36-1.26)
Italy	46	57	0.81	(0.54-1.18)
Malta	11	13	0.85	(0.33-1.75)
Greece	23	25	0.91	(0.50-1.52)
Netherlands	15	14	1.09	(0.50-2.05)
Poland	16	12	1.33	(0.63-2.45)
China	16	7	2.14	(1.01-3.94)
Lebanon	15	6	2.66	(1.22-5.00)

Table A5.2: Cases, standardised incidence ratios compared to females living in their place of birth and 99% confidence intervals for breast cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Females				
Malta	186	200	0.93	(0.76-1.12)
Netherlands	249	263	0.95	(0.80-1.11)
New Zealand	519	495	1.05	(0.93-1.17)
Yugoslavia	365	339	1.08	(0.94-1.23)
United Kingdom and Ireland	3,065	2,743	1.12	(1.07-1.17)
Italy	639	565	1.13	(1.02-1.25)
Germany	395	338	1.17	(1.02-1.33)
United States of America	107	89	1.20	(0.92-1.53)
Poland	145	100	1.45	(1.16-1.79)
Greece	429	285	1.51	(1.33-1.71)
Portugal	67	40	1.66	(1.18-2.25)
Malaysia and Brunei	113	65	1.74	(1.35-2.21)
Philippines	288	159	1.81	(1.54-2.10)
Korea	42	20	2.05	(1.33-3.01)
Hong Kong and Macau	130	59	2.21	(1.74-2.76)
Lebanon	237	105	2.25	(1.89-2.65)
Vietnam	149	64	2.34	(1.88-2.89)
Spain	68	27	2.48	(1.78-3.37)
South Africa	146	56	2.60	(2.08-3.20)
Indonesia	77	28	2.71	(1.98-3.61)
Fiji	96	35	2.71	(2.05-3.51)
Sri Lanka	57	20	2.89	(2.00-4.03)
China	296	88	3.35	(2.87-3.89)
Egypt	201	57	3.52	(2.91-4.21)
India	166	45	3.71	(3.01-4.52)

Table A5.3: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for cancers of the brain and central nervous system by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Vietnam	3	13	0.22	(0.03-0.82)
Yugoslavia	49	75	0.65	(0.44-0.93)
Greece	48	58	0.82	(0.55-1.18)
New Zealand	32	34	0.94	(0.56-1.45)
Lebanon	26	23	1.14	(0.64-1.85)
Malta	17	14	1.20	(0.58-2.17)
China	17	14	1.25	(0.61-2.26)
Italy	70	56	1.26	(0.90-1.70)
Germany	31	23	1.35	(0.81-2.11)
Netherlands	27	18	1.49	(0.85-2.40)
United Kingdom and Ireland	225	140	1.60	(1.34-1.90)
Egypt	11	6	1.73	(0.68-3.59)
India	13	6	2.16	(0.93-4.23)
Poland	29	10	3.00	(1.76-4.75)
Females				
New Zealand	14	28	0.51	(0.23-0.97)
Greece	24	33	0.72	(0.40-1.20)
China	11	13	0.83	(0.33-1.73)
Germany	18	18	0.98	(0.49-1.75)
United Kingdom and Ireland	158	129	1.23	(0.99-1.50)
Italy	46	31	1.49	(0.99-2.16)
Yugoslavia	29	19	1.49	(0.88-2.37)
Netherlands	20	9	2.27	(1.17-3.93)
Egypt	11	4	2.75	(1.08-5.69)

Table A5.4: Cases, standardised incidence ratios compared to females living in their place of birth and 99% confidence intervals for cervical cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Females				
South Africa	5	56	0.09	(0.02-0.25)
Sri Lanka	4	29	0.14	(0.02-0.43)
India	10	66	0.15	(0.06-0.33)
Italy	29	63	0.46	(0.27-0.73)
Poland	19	40	0.48	(0.24-0.84)
Hong Kong and Macau	12	25	0.48	(0.20-0.97)
Malaysia and Brunei	10	20	0.51	(0.19-1.08)
Fiji	27	53	0.51	(0.29-0.83)
Yugoslavia	58	103	0.56	(0.39-0.78)
Korea	17	27	0.63	(0.30-1.13)
Germany	26	42	0.63	(0.35-1.02)
Lebanon	19	28	0.68	(0.35-1.19)
Malta	9	13	0.69	(0.24-1.54)
Philippines	58	84	0.69	(0.48-0.96)
Egypt	15	21	0.70	(0.32-1.31)
Greece	26	36	0.72	(0.41-1.17)
United Kingdom and Ireland	254	308	0.82	(0.70-0.97)
Vietnam	53	58	0.91	(0.62-1.28)
New Zealand	73	78	0.94	(0.68-1.26)
Indonesia	17	18	0.97	(0.47-1.75)
Netherlands	15	15	0.99	(0.45-1.85)
United States of America	11	10	1.13	(0.44-2.34)
China	64	34	1.91	(1.35-2.61)

Table A5.5: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for colorectal cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Netherlands	159	201	0.79	(0.64-0.97)
Malaysia and Brunei	23	25	0.92	(0.50-1.53)
Germany	207	207	1.00	(0.83-1.20)
United States of America	48	42	1.15	(0.77-1.65)
Philippines	49	42	1.16	(0.78-1.66)
Malta	100	86	1.17	(0.89-1.50)
Italy	625	504	1.24	(1.12-1.37)
New Zealand	273	216	1.26	(1.07-1.47)
Sri Lanka	19	14	1.35	(0.68-2.37)
Portugal	35	26	1.35	(0.84-2.06)
Hong Kong and Macau	49	35	1.41	(0.94-2.01)
Korea	27	18	1.49	(0.86-2.41)
Spain	39	25	1.56	(0.99-2.32)
Vietnam	49	31	1.59	(1.07-2.27)
United Kingdom and Ireland	1,909	1,170	1.63	(1.54-1.73)
Yugoslavia	319	193	1.66	(1.43-1.91)
Greece	244	129	1.89	(1.59-2.23)
Indonesia	24	12	2.08	(1.15-3.45)
China	204	85	2.41	(2.00-2.88)
South Africa	32	13	2.42	(1.46-3.76)
Poland	216	88	2.47	(2.06-2.93)
Fiji	24	10	2.48	(1.37-4.10)
Lebanon	92	25	3.72	(2.79-4.84)
India	47	12	4.01	(2.66-5.78)
Egypt	74	13	5.65	(4.10-7.57)
Females				
Netherlands	100	116	0.86	(0.66-1.11)
New Zealand	219	246	0.89	(0.74-1.06)
Germany	189	195	0.97	(0.80-1.17)
Malta	68	65	1.04	(0.75-1.42)
Malaysia and Brunei	27	26	1.05	(0.60-1.70)
Italy	306	282	1.09	(0.93-1.26)
United Kingdom and Ireland	1,457	1,316	1.11	(1.03-1.18)
Hong Kong and Macau	38	32	1.19	(0.75-1.79)
Philippines	49	41	1.20	(0.80-1.72)
Yugoslavia	164	135	1.22	(0.98-1.48)
United States of America	37	26	1.41	(0.89-2.13)
Poland	104	69	1.50	(1.15-1.92)
Portugal	25	16	1.56	(0.87-2.55)
Vietnam	44	26	1.67	(1.09-2.44)
Spain	23	13	1.73	(0.94-2.90)
Korea	22	12	1.76	(0.95-2.98)
Greece	162	90	1.81	(1.46-2.20)
Fiji	23	11	2.06	(1.12-3.45)
Indonesia	21	10	2.08	(1.10-3.56)
South Africa	35	16	2.24	(1.38-3.41)
China	175	71	2.48	(2.02-3.01)
Lebanon	47	18	2.69	(1.78-3.87)
India	41	8	5.18	(3.33-7.64)
Egypt	51	8	6.33	(4.28-8.99)
Sri Lanka	17	2	8.98	(4.36-16.27)

Table A5.6: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for head and neck cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Korea	3	15	0.20	(0.02-0.72)
Sri Lanka	7	36	0.20	(0.06-0.48)
India	19	66	0.29	(0.15-0.50)
South Africa	13	43	0.30	(0.13-0.59)
Yugoslavia	101	270	0.37	(0.29-0.48)
Portugal	10	26	0.38	(0.14-0.81)
Malta	23	54	0.42	(0.23-0.71)
Germany	56	124	0.45	(0.31-0.63)
Philippines	21	41	0.51	(0.27-0.88)
Italy	166	322	0.52	(0.42-0.63)
New Zealand	61	118	0.52	(0.36-0.71)
Greece	46	88	0.52	(0.35-0.76)
Lebanon	42	75	0.56	(0.36-0.83)
Netherlands	36	59	0.61	(0.38-0.92)
Poland	45	73	0.62	(0.41-0.90)
Spain	12	19	0.62	(0.26-1.26)
United States of America	16	25	0.63	(0.30-1.16)
Hong Kong and Macau	39	59	0.66	(0.42-0.98)
Malaysia and Brunei	19	23	0.82	(0.42-1.44)
Vietnam	50	54	0.92	(0.62-1.31)
United Kingdom and Ireland	586	551	1.06	(0.95-1.18)
Egypt	20	16	1.22	(0.63-2.12)
China	86	38	2.26	(1.68-2.96)
Fiji	15	5	2.80	(1.29-5.26)
Females				
Sri Lanka	2	16	0.13	(0.01-0.59)
India	3	23	0.13	(0.01-0.48)
Yugoslavia	12	27	0.45	(0.18-0.90)
Hong Kong and Macau	12	24	0.49	(0.20-0.99)
Netherlands	10	16	0.64	(0.24-1.37)
Philippines	24	34	0.70	(0.39-1.16)
Germany	20	24	0.83	(0.43-1.45)
New Zealand	32	37	0.88	(0.53-1.36)
Vietnam	22	25	0.90	(0.48-1.52)
Malta	11	10	1.07	(0.42-2.22)
Italy	35	30	1.17	(0.72-1.79)
United Kingdom and Ireland	199	160	1.25	(1.03-1.49)
Greece	16	12	1.33	(0.63-2.45)
Malaysia and Brunei	17	10	1.74	(0.85-3.16)
Lebanon	20	8	2.55	(1.32-4.42)
China	45	16	2.76	(1.82-4.01)

Table A5.7: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for kidney cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
United States of America	8	11	0.71	(0.23-1.64)
Yugoslavia	48	62	0.77	(0.52-1.11)
Netherlands	31	36	0.85	(0.51-1.33)
Germany	55	58	0.94	(0.65-1.32)
Italy	136	136	1.00	(0.79-1.24)
Vietnam	11	11	1.02	(0.40-2.11)
New Zealand	41	38	1.07	(0.69-1.57)
Malta	32	22	1.45	(0.88-2.25)
Philippines	12	6	1.88	(0.77-3.78)
Greece	86	46	1.89	(1.41-2.48)
United Kingdom and Ireland	410	210	1.95	(1.71-2.21)
Spain	12	5	2.28	(0.94-4.59)
Lebanon	42	16	2.62	(1.70-3.86)
China	29	11	2.63	(1.54-4.18)
Portugal	11	4	2.68	(1.05-5.54)
Poland	68	24	2.80	(2.00-3.80)
South Africa	12	3	3.72	(1.53-7.49)
Egypt	26	5	5.49	(3.12-8.93)
India	15	3	5.59	(2.57-10.50)
Females				
New Zealand	20	27	0.73	(0.38-1.26)
Italy	47	43	1.10	(0.73-1.58)
Yugoslavia	27	23	1.16	(0.67-1.87)
Germany	37	31	1.18	(0.74-1.78)
Poland	20	15	1.32	(0.69-2.30)
Netherlands	26	19	1.38	(0.79-2.25)
Malta	14	10	1.43	(0.64-2.74)
United Kingdom and Ireland	254	153	1.66	(1.40-1.95)
Philippines	12	6	1.94	(0.80-3.91)
Greece	37	15	2.40	(1.50-3.61)
Lebanon	17	6	2.87	(1.39-5.21)
China	29	6	4.98	(2.92-7.90)
Vietnam	11	2	7.33	(2.88-15.18)

Table A5.8: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for leukaemia by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Malta	22	24	0.92	(0.50-1.56)
Greece	52	53	0.99	(0.67-1.40)
Lebanon	32	32	1.01	(0.61-1.57)
New Zealand	46	43	1.08	(0.71-1.56)
Netherlands	35	31	1.13	(0.70-1.72)
Germany	36	32	1.14	(0.71-1.72)
Philippines	16	13	1.26	(0.60-2.33)
Vietnam	21	16	1.30	(0.69-2.23)
Italy	131	97	1.34	(1.06-1.68)
Yugoslavia	63	43	1.46	(1.03-2.00)
United Kingdom and Ireland	335	225	1.49	(1.29-1.71)
Egypt	15	9	1.60	(0.73-3.00)
China	33	20	1.66	(1.01-2.56)
United States of America	19	10	1.89	(0.96-3.32)
Poland	41	18	2.26	(1.45-3.33)
South Africa	17	6	2.71	(1.31-4.90)
India	21	7	3.17	(1.67-5.43)
Malaysia and Brunei	19	6	3.29	(1.67-5.79)
Indonesia	13	4	3.64	(1.56-7.14)
Females				
Germany	24	25	0.96	(0.53-1.60)
Vietnam	11	11	1.03	(0.40-2.13)
Malta	13	13	1.03	(0.44-2.02)
New Zealand	41	38	1.07	(0.69-1.58)
Poland	15	14	1.10	(0.50-2.06)
Greece	29	26	1.10	(0.64-1.74)
Yugoslavia	29	25	1.14	(0.67-1.81)
United Kingdom and Ireland	268	213	1.26	(1.07-1.47)
Italy	68	52	1.32	(0.94-1.79)
Philippines	22	16	1.36	(0.73-2.31)
Netherlands	18	13	1.41	(0.70-2.51)
Egypt	12	7	1.63	(0.67-3.28)
Lebanon	30	13	2.29	(1.36-3.61)
China	35	15	2.35	(1.45-3.58)
Fiji	11	4	2.96	(1.16-6.12)

Table A5.9: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for liver cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
New Zealand	11	54	0.20	(0.08-0.42)
Poland	9	40	0.22	(0.08-0.50)
United Kingdom and Ireland	103	390	0.26	(0.20-0.34)
Greece	26	97	0.27	(0.15-0.44)
Fiji	4	11	0.36	(0.06-1.14)
Lebanon	6	14	0.44	(0.11-1.15)
Italy	87	191	0.46	(0.34-0.60)
Korea	25	52	0.48	(0.27-0.79)
Hong Kong and Macau	22	44	0.49	(0.27-0.84)
China	119	218	0.55	(0.43-0.69)
Malaysia and Brunei	9	16	0.57	(0.20-1.26)
Germany	14	19	0.73	(0.32-1.39)
Yugoslavia	37	28	1.32	(0.83-1.99)
Egypt	25	17	1.45	(0.81-2.38)
Indonesia	16	10	1.54	(0.73-2.83)
Vietnam	86	53	1.62	(1.21-2.13)
Philippines	14	5	3.01	(1.34-5.78)
Females				
Yugoslavia	6	106	0.06	(0.01-0.15)
Hong Kong and Macau	2	11	0.18	(0.01-0.84)
Philippines	6	22	0.27	(0.07-0.72)
Greece	10	32	0.32	(0.12-0.67)
Poland	6	15	0.41	(0.10-1.06)
China	38	88	0.43	(0.27-0.64)
Italy	29	56	0.52	(0.30-0.82)
United Kingdom and Ireland	38	51	0.74	(0.47-1.11)
Korea	10	12	0.83	(0.31-1.78)
Vietnam	32	19	1.64	(0.99-2.55)

Table A5.10: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for lung cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Sri Lanka	6	22	0.27	(0.07-0.71)
Korea	17	45	0.38	(0.18-0.69)
Hong Kong and Macau	27	65	0.41	(0.24-0.67)
Yugoslavia	353	649	0.54	(0.47-0.62)
United States of America	44	74	0.60	(0.39-0.87)
Malaysia and Brunei	22	33	0.67	(0.36-1.14)
Greece	299	441	0.68	(0.58-0.79)
Italy	627	920	0.68	(0.61-0.76)
Vietnam	95	123	0.77	(0.58-1.00)
New Zealand	180	231	0.78	(0.64-0.94)
Portugal	25	30	0.82	(0.46-1.35)
China	217	247	0.88	(0.73-1.04)
Spain	39	44	0.89	(0.57-1.33)
Germany	216	239	0.91	(0.75-1.08)
Poland	189	202	0.93	(0.77-1.12)
Netherlands	245	261	0.94	(0.79-1.10)
Lebanon	115	121	0.95	(0.74-1.20)
South Africa	28	25	1.13	(0.65-1.80)
Malta	185	148	1.25	(1.02-1.50)
United Kingdom and Ireland	2,385	1,892	1.26	(1.20-1.33)
Indonesia	30	19	1.56	(0.92-2.46)
Fiji	16	8	1.90	(0.90-3.51)
India	41	21	1.92	(1.23-2.83)
Philippines	63	32	1.96	(1.38-2.69)
Egypt	59	26	2.24	(1.56-3.11)
Females				
Yugoslavia	56	282	0.20	(0.14-0.28)
United States of America	16	28	0.57	(0.27-1.06)
Greece	35	56	0.63	(0.39-0.96)
Hong Kong and Macau	22	31	0.71	(0.38-1.19)
Malaysia and Brunei	11	15	0.75	(0.29-1.55)
Philippines	37	44	0.85	(0.53-1.28)
Italy	94	105	0.89	(0.67-1.16)
New Zealand	123	123	1.00	(0.79-1.26)
Korea	12	12	1.02	(0.42-2.06)
United Kingdom and Ireland	1,162	1,116	1.04	(0.96-1.12)
China	125	111	1.13	(0.88-1.41)
Vietnam	34	22	1.56	(0.96-2.39)
Poland	66	42	1.57	(1.12-2.15)
Netherlands	85	52	1.65	(1.22-2.17)
South Africa	24	13	1.78	(0.98-2.95)
Germany	107	56	1.92	(1.47-2.45)
Fiji	17	9	1.99	(0.97-3.61)
Indonesia	15	7	2.24	(1.03-4.20)
Egypt	20	8	2.50	(1.29-4.33)
Lebanon	31	11	2.70	(1.61-4.22)
Malta	36	13	2.77	(1.72-4.19)
India	37	5	7.77	(4.87-11.70)

Table A5.11: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for melanoma of the skin by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Yugoslavia	40	42	0.95	(0.61-1.42)
New Zealand	143	142	1.01	(0.80-1.25)
Netherlands	58	49	1.19	(0.83-1.66)
Italy	63	41	1.55	(1.09-2.13)
United States of America	23	13	1.83	(0.99-3.06)
Greece	22	9	2.44	(1.31-4.13)
Poland	38	15	2.62	(1.65-3.93)
Germany	73	24	3.06	(2.22-4.11)
United Kingdom and Ireland	587	134	4.37	(3.92-4.86)
South Africa	33	6	5.21	(3.17-8.03)
China	14	2	8.78	(3.91-16.83)
Egypt	12	0	287.42	(118.39-578.30)
Females				
New Zealand	130	210	0.62	(0.49-0.77)
Italy	50	44	1.13	(0.76-1.61)
United States of America	12	9	1.29	(0.53-2.59)
Netherlands	35	26	1.36	(0.84-2.08)
Germany	41	30	1.39	(0.89-2.05)
United Kingdom and Ireland	371	247	1.50	(1.31-1.72)
Greece	18	12	1.55	(0.77-2.76)
Poland	20	11	1.77	(0.92-3.07)
Yugoslavia	21	12	1.79	(0.94-3.07)
South Africa	19	8	2.37	(1.20-4.16)

Table A5.12: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for non-Hodgkin lymphoma by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
United States of America	12	15	0.82	(0.34-1.65)
Hong Kong and Macau	12	12	1.00	(0.41-2.02)
Netherlands	44	39	1.14	(0.74-1.66)
Germany	46	39	1.17	(0.77-1.69)
New Zealand	74	62	1.20	(0.87-1.61)
Philippines	16	13	1.23	(0.58-2.26)
Italy	168	137	1.23	(1.00-1.49)
Lebanon	42	32	1.29	(0.84-1.90)
Yugoslavia	69	47	1.47	(1.06-2.00)
Malta	41	28	1.48	(0.95-2.19)
Malaysia and Brunei	14	8	1.75	(0.78-3.36)
United Kingdom and Ireland	537	299	1.80	(1.60-2.01)
Poland	40	21	1.87	(1.20-2.78)
India	14	7	1.88	(0.83-3.60)
Vietnam	37	16	2.37	(1.49-3.57)
South Africa	16	5	3.02	(1.43-5.57)
Spain	18	6	3.17	(1.57-5.64)
Greece	92	29	3.21	(2.41-4.18)
Indonesia	21	6	3.67	(1.94-6.29)
China	57	13	4.46	(3.09-6.22)
Egypt	34	6	5.67	(3.48-8.69)
Females				
New Zealand	57	57	1.00	(0.69-1.39)
Netherlands	29	24	1.21	(0.71-1.91)
Italy	98	76	1.28	(0.97-1.66)
United Kingdom and Ireland	388	293	1.32	(1.16-1.51)
Germany	42	31	1.35	(0.88-1.99)
Vietnam	15	8	1.79	(0.82-3.36)
Malaysia and Brunei	14	6	2.35	(1.04-4.50)
Philippines	26	11	2.45	(1.39-3.98)
Yugoslavia	48	20	2.45	(1.64-3.52)
Malta	45	18	2.49	(1.64-3.61)
South Africa	14	5	2.55	(1.13-4.89)
Lebanon	37	14	2.60	(1.63-3.92)
Poland	33	12	2.76	(1.68-4.25)
India	13	4	3.28	(1.41-6.44)
Greece	58	16	3.52	(2.45-4.90)
Indonesia	16	4	4.27	(2.02-7.87)
Egypt	19	4	4.83	(2.45-8.49)
China	42	8	5.20	(3.37-7.65)

Table A5.13: Cases, standardised incidence ratios compared to females living in their place of birth and 99% confidence intervals for ovarian cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Females				
New Zealand	47	73	0.65	(0.43-0.93)
Yugoslavia	56	78	0.72	(0.49-1.00)
Malaysia and Brunei	13	18	0.74	(0.32-1.45)
Malta	24	32	0.74	(0.41-1.23)
United Kingdom and Ireland	386	496	0.78	(0.68-0.89)
Netherlands	29	36	0.80	(0.47-1.27)
Italy	70	85	0.83	(0.60-1.12)
Germany	49	56	0.87	(0.59-1.25)
Philippines	31	35	0.88	(0.52-1.37)
Greece	43	42	1.03	(0.67-1.51)
Vietnam	17	16	1.04	(0.51-1.89)
Hong Kong and Macau	15	13	1.14	(0.52-2.13)
Indonesia	12	9	1.35	(0.56-2.72)
Fiji	13	10	1.37	(0.59-2.68)
Poland	42	30	1.39	(0.90-2.05)
Lebanon	18	12	1.50	(0.75-2.68)
United States of America	17	11	1.60	(0.78-2.90)
India	19	11	1.68	(0.85-2.95)
China	41	18	2.25	(1.45-3.33)
South Africa	17	7	2.27	(1.10-4.11)
Egypt	23	2	10.06	(5.48-16.84)

Table A5.14: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for pancreatic cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Netherlands	21	28	0.74	(0.39-1.27)
Yugoslavia	48	61	0.79	(0.53-1.14)
Italy	85	106	0.81	(0.60-1.06)
New Zealand	25	29	0.85	(0.48-1.40)
Germany	32	33	0.97	(0.58-1.50)
Malta	28	27	1.04	(0.60-1.66)
Lebanon	23	20	1.17	(0.64-1.96)
Greece	65	47	1.38	(0.98-1.89)
United Kingdom and Ireland	303	205	1.48	(1.27-1.71)
Vietnam	18	11	1.59	(0.79-2.84)
China	39	21	1.83	(1.16-2.73)
Poland	42	23	1.84	(1.19-2.71)
Egypt	15	6	2.59	(1.19-4.87)
India	11	3	3.17	(1.25-6.57)
Females				
Netherlands	19	20	0.94	(0.48-1.66)
Yugoslavia	32	30	1.07	(0.64-1.65)
United Kingdom and Ireland	295	276	1.07	(0.92-1.24)
Germany	33	30	1.08	(0.66-1.67)
Italy	70	63	1.11	(0.80-1.50)
New Zealand	37	33	1.13	(0.71-1.70)
Greece	28	24	1.15	(0.67-1.84)
Poland	25	21	1.19	(0.67-1.95)
Philippines	12	10	1.20	(0.50-2.42)
Malta	21	13	1.60	(0.84-2.74)
Lebanon	18	11	1.65	(0.82-2.94)
China	38	16	2.34	(1.48-3.51)
Vietnam	11	3	3.82	(1.50-7.90)
Egypt	15	3	5.69	(2.62-10.69)
India	13	2	5.97	(2.56-11.70)

Table A5.15: Cases, standardised incidence ratios compared to males living in their place of birth and 99% confidence intervals for prostate cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
New Zealand	340	343	0.99	(0.86-1.14)
United States of America	86	81	1.06	(0.79-1.40)
Netherlands	287	244	1.18	(1.00-1.37)
Sri Lanka	32	27	1.18	(0.71-1.83)
Germany	330	222	1.49	(1.28-1.71)
Yugoslavia	326	197	1.66	(1.43-1.91)
Malta	145	83	1.76	(1.40-2.17)
Portugal	35	18	1.93	(1.19-2.94)
Philippines	53	27	1.95	(1.33-2.75)
Poland	299	142	2.10	(1.80-2.44)
Italy	845	377	2.24	(2.05-2.45)
South Africa	82	36	2.26	(1.67-2.99)
Spain	45	20	2.29	(1.50-3.32)
Greece	353	145	2.43	(2.11-2.78)
United Kingdom and Ireland	3,231	1,280	2.52	(2.41-2.64)
Vietnam	42	14	2.93	(1.90-4.31)
Korea	15	4	3.91	(1.80-7.34)
Lebanon	159	34	4.69	(3.78-5.73)
Fiji	40	8	5.11	(3.27-7.58)
Malaysia and Brunei	41	7	6.04	(3.89-8.92)
Hong Kong and Macau	40	5	7.95	(5.09-11.80)
Indonesia	44	5	8.03	(5.26-11.71)
India	92	11	8.65	(6.50-11.25)
Egypt	150	16	9.53	(7.64-11.72)
China	177	11	15.85	(12.95-19.19)

Table A5.16: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for stomach cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
United States of America	3	16	0.19	(0.02-0.68)
Philippines	6	28	0.21	(0.05-0.56)
China	92	249	0.37	(0.28-0.48)
Korea	37	74	0.50	(0.31-0.76)
Vietnam	35	68	0.51	(0.32-0.78)
Portugal	10	19	0.54	(0.20-1.15)
Italy	169	311	0.54	(0.44-0.66)
Netherlands	35	57	0.62	(0.38-0.94)
Malta	26	42	0.63	(0.35-1.02)
Hong Kong and Macau	13	19	0.70	(0.30-1.37)
Lebanon	25	32	0.78	(0.43-1.27)
Yugoslavia	130	161	0.81	(0.64-1.01)
Malaysia and Brunei	10	12	0.81	(0.30-1.73)
United Kingdom and Ireland	562	663	0.85	(0.76-0.94)
Spain	11	13	0.85	(0.33-1.76)
Germany	72	80	0.90	(0.65-1.21)
New Zealand	46	50	0.92	(0.61-1.33)
Poland	70	72	0.97	(0.70-1.31)
India	14	14	1.03	(0.46-1.96)
Greece	99	92	1.08	(0.82-1.39)
South Africa	14	9	1.61	(0.71-3.08)
Egypt	18	11	1.65	(0.82-2.94)
Females				
China	61	132	0.46	(0.32-0.64)
Germany	28	57	0.49	(0.29-0.79)
Netherlands	12	23	0.52	(0.21-1.05)
Italy	70	131	0.53	(0.38-0.72)
Korea	18	29	0.62	(0.31-1.11)
Philippines	11	17	0.64	(0.25-1.32)
New Zealand	22	32	0.70	(0.37-1.18)
Vietnam	25	35	0.72	(0.40-1.18)
Hong Kong and Macau	9	12	0.76	(0.26-1.68)
United Kingdom and Ireland	257	335	0.77	(0.65-0.90)
Yugoslavia	60	72	0.84	(0.58-1.16)
Poland	32	38	0.84	(0.51-1.31)
Malta	17	17	0.97	(0.47-1.76)
Greece	51	43	1.19	(0.80-1.69)
Malaysia and Brunei	12	9	1.35	(0.55-2.71)
Lebanon	18	12	1.49	(0.74-2.66)
South Africa	13	7	1.91	(0.82-3.74)

Table A5.17: Cases, standardised incidence ratios compared to males living in their place of birth and 99% confidence intervals for testicular cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
Italy	8	16	0.49	(0.16-1.13)
Yugoslavia	14	17	0.84	(0.37-1.61)
Germany	17	17	0.97	(0.47-1.76)
United Kingdom and Ireland	158	78	2.03	(1.64-2.49)
New Zealand	72	32	2.23	(1.61-3.01)
Lebanon	22	4	6.17	(3.31-10.44)

Table A5.18: Cases, standardised incidence ratios compared to males and females living in their place of birth and 99% confidence intervals for thyroid cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Males				
New Zealand	8	14	0.56	(0.18-1.31)
United Kingdom and Ireland	45	33	1.36	(0.89-1.97)
Yugoslavia	14	9	1.64	(0.73-3.14)
Italy	28	11	2.46	(1.43-3.93)
Philippines	14	4	3.52	(1.56-6.74)
Lebanon	24	6	3.84	(2.12-6.35)
Greece	24	4	6.60	(3.64-10.93)
China	19	3	7.03	(3.57-12.34)
Females				
New Zealand	34	34	1.00	(0.61-1.53)
Germany	16	13	1.25	(0.59-2.30)
Italy	53	39	1.38	(0.94-1.94)
Hong Kong and Macau	24	15	1.56	(0.86-2.59)
Malaysia and Brunei	15	10	1.57	(0.72-2.95)
Fiji	17	9	1.97	(0.96-3.57)
United Kingdom and Ireland	125	62	2.02	(1.59-2.54)
Korea	18	8	2.16	(1.07-3.85)
Yugoslavia	43	18	2.34	(1.52-3.42)
Poland	14	6	2.36	(1.05-4.53)
Indonesia	13	5	2.64	(1.13-5.18)
Philippines	83	31	2.72	(2.01-3.59)
Greece	47	12	3.77	(2.50-5.43)
India	17	4	4.11	(1.99-7.44)
Lebanon	56	13	4.16	(2.87-5.82)
Sri Lanka	11	2	4.48	(1.76-9.28)
China	40	8	5.15	(3.29-7.64)
Vietnam	53	10	5.22	(3.56-7.37)
Portugal	14	2	5.84	(2.60-11.19)

Table A5.19: Cases, standardised incidence ratios compared to females living in their place of birth and 99% confidence intervals for uterine cancer by place of birth, NSW 1991 to 2001

Place of birth	Cases	Expected	SIR	99% CI
Females				
Netherlands	25	40	0.62	(0.35-1.01)
Malta	32	50	0.64	(0.39-1.00)
United States of America	9	14	0.64	(0.22-1.43)
Italy	103	155	0.66	(0.51-0.85)
Yugoslavia	62	92	0.68	(0.48-0.93)
Germany	51	61	0.83	(0.56-1.19)
New Zealand	56	62	0.91	(0.63-1.27)
United Kingdom and Ireland	367	397	0.92	(0.80-1.06)
South Africa	11	10	1.15	(0.45-2.37)
Malaysia and Brunei	13	10	1.27	(0.55-2.50)
Lebanon	20	15	1.35	(0.70-2.35)
Poland	46	33	1.40	(0.93-2.03)
Greece	72	46	1.57	(1.14-2.11)
Hong Kong and Macau	18	11	1.66	(0.82-2.96)
Philippines	36	20	1.84	(1.15-2.79)
Fiji	17	8	2.18	(1.06-3.94)
Vietnam	18	8	2.28	(1.13-4.06)
China	37	12	2.97	(1.87-4.48)
India	32	4	7.72	(4.66-11.98)
Egypt	31	4	8.67	(5.18-13.54)

Appendix 6: Calculation of standardised incidence ratios and confidence intervals

Standardised incidence ratios

For comparisons between people in a study population and those from a standard population standardised incidence ratios (SIRs) can be calculated. These are the ratios of the observed number of new cases in the study population to the number expected, based on age-specific rates in a standard population for the period 1991 to 2001.

To calculate the standardised incidence ratio for a study population compared to the standard population, first the age-specific incidence rates in the standard population (R_i) were calculated by dividing the number of cases observed (C_i) for the time period by the age specific population (P_i).

$$R_i = \frac{C_i}{P_i}$$

The actual number of cancer cases observed by place of birth for the time period ($\sum C_i$) were then divided by the expected number of cases for that place of birth. The expected cases were calculated by multiplying the standard population age-specific rates R_i by the size of the population in that age group for each place of birth (p_i). The sum of these products is the expected number of cases in the study population, as defined by their place of birth, if they had the same rates as the standard population. For this report the study population was defined by place of birth. Two standard populations were used for comparisons: the Australian-born population in NSW and the population resident in the respective places of birth.

$$SIR = \frac{\sum_i C_i}{\sum_i R_i p_i}$$

This is the standardised incidence ratio (SIR). An SIR greater than 1 indicates that more than the expected number of cases was observed for the study population. Conversely, a number lower than 1 indicates that the number of cases of cancer observed in the study population was less than that expected based on rates in the standard population.

Confidence intervals

Confidence intervals (CI) indicate the level of precision of an estimate of the standardised incidence ratio. For example, an SIR of 2.1 with a 99% CI of 1.6-2.6 indicates that 2.1 is the best estimate of the ratio, and that the interval 1.6-2.6 has a 99% chance of encompassing the true value of the ratio.

Confidence intervals for SIRs were calculated using the method described by Ulm⁽⁹⁾ using a Poisson distribution. Poisson confidence intervals are often asymmetric for rates less than 1 and where the number of observations were less than 100.

The confidence interval is calculated using the formula given below where LL and UL are lower and upper confidence limits respectively for the ratio, $\chi^2(\alpha, v)$ is the value of the chi-square distribution with v degrees of freedom corresponding to the $100\alpha\%$ in the tail, and d is the number of observed cases ($d = \sum C_i$).

We then divided these chi-squared values by the expected number of cases to get the confidence limits for the SIR. We consider the expected number of cases ($E = \sum R_i p_i$) to be constant as they are based on the standard population age specific incidence rates.

$$LL = \frac{\chi^2_{\alpha/2, 2d}}{2E}$$

$$UL = \frac{\chi^2_{\alpha/2, 2(d+1)}}{2E}$$

Appendix 7: References

1. McCredie M, Coates M, Duque-Portugal F, Smith D, Taylor R. Common Cancers in Migrants to New South Wales 1972-1990. 1993. Sydney: The Cancer Council NSW.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: International Agency for Research on Cancer, IARC Press. (1.0), 2001. www.iarc.fr
3. Thomas DB, Karagas M. Migrant studies. in: Cancer Epidemiology and Prevention. Schottenfeld D and Fraumeni JF. Oxford: Oxford University Press. Second Edition, 1996.
4. Kendig H, Andrews G, Browning C, Quine S, Parsons A. A review of healthy ageing research in Australia. 2001. Canberra: Commonwealth Department of Health and Aged Care.
5. Armstrong BK, Woodings TL, Stenhouse NS, McCall MG. Mortality from cancer in migrants to Australia 1962-1971. 1983. Perth: NHMRC Research Unit in Epidemiology and Preventative Medicine, University of Western Australia.
6. McMichael AJ, Giles GG. Cancer in migrants to Australia: Extending the descriptive epidemiological data. *Cancer Research* 1988;48:751-756.
7. Parkin DM, Pisani P, Ferlay J. Estimate of the worldwide incidence of 25 major cancers in 1990. *International Journal of Cancer* 1999;80 (6):827-841.
8. Esteve J, Benhamou E, Raymond L. Statistical methods in cancer research Volume IV: Descriptive Epidemiology. IARC Scientific Publications. Lyon: International Agency for Research on Cancer. (128), 1994.
9. Ulm K. A simple method to calculate the confidence interval of a standardised mortality ratio (SMR). *American Journal of Epidemiology* 1990;131 (2):373-375.
10. Gill PS, Bhopal R, Wild S, Kai J. Limitations and potential of place of birth as proxy for ethnic group. *BMJ* 2005;330 (7484):196.